VYNE Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
VYNE Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.66 |
| 52 Week High | US$7.48 |
| 52 Week Low | US$1.67 |
| Beta | 1.48 |
| 1 Month Change | 13.19% |
| 3 Month Change | 22.58% |
| 1 Year Change | -61.73% |
| 3 Year Change | -95.93% |
| 5 Year Change | n/a |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10VYNE Therapeutics closes capital raise of $50M
Jan 29What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?
Jan 06VYNE Therapeutics reports successful FDA meeting for FCD105 in acne
Dec 17Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?
Dec 08Shareholder Returns
| VYNE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.6% | 0.5% | -0.2% |
| 1Y | -61.7% | 17.9% | 28.2% |
Return vs Industry: VYNE underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: VYNE underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| VYNE volatility | |
|---|---|
| VYNE Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VYNE's share price has been volatile over the past 3 months.
Volatility Over Time: VYNE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Dave Domzalski | www.vynetherapeutics.com |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.
VYNE Therapeutics Inc. Fundamentals Summary
| VYNE fundamental statistics | |
|---|---|
| Market cap | US$38.07m |
| Earnings (TTM) | -US$28.65m |
| Revenue (TTM) | US$423.00k |
88.7x
P/S Ratio-1.3x
P/E RatioIs VYNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYNE income statement (TTM) | |
|---|---|
| Revenue | US$423.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$423.00k |
| Other Expenses | US$29.07m |
| Earnings | -US$28.65m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -6,773.05% |
| Debt/Equity Ratio | 0% |
How did VYNE perform over the long term?
See historical performance and comparison